The ACCV consists of nine voting members appointed by the Secretary as follows: (1) Three health professionals, who are not employees of the U.S. government, and who have expertise in the health care of children, the epidemiology, etiology, and prevention of childhood diseases, and the adverse reactions associated with vaccines, of whom at least two shall be pediatricians; (2) three members from the general public, of whom at least two shall be legal representatives (parents or guardians) of children who have suffered a vaccine-related injury or death; and (3) three attorneys, of whom at least one shall be an attorney whose specialty includes representation of persons who have suffered a vaccine-related injury or death, and of whom one shall be an attorney whose specialty includes representation of vaccine manufacturers. In addition, the Director of the National Institutes of Health, the Assistant Secretary for Health, the Director of the Centers for Disease Control and Prevention, and the Commissioner of the Food and Drug Administration (or the designees of such officials) serve as non-voting ex officio members.

HHS will consider nominations of all qualified individuals with a view to ensure that the ACCV includes the areas of subject matter expertise noted above. As indicated above, at least two of the three ACCV members of the general public shall be legal representatives (parents or guardians) of children who have suffered a vaccine-related injury or death. Because those members must be the legal representatives of children who have suffered a vaccine-related injury or death, to be considered for appointment to the ACCV in that category, there must have been a finding (i.e., a decision) by the U.S. Court of Federal Claims or a civil court that a VICP-covered vaccine caused, or was presumed to have caused, the represented child’s injury or death. Additionally, based on a recommendation made by the ACCV, the Secretary will consider having a health professional with expertise in obstetrics as one of the members of the general public. Interested applicants may self-nominate or be nominated by another individual or organization.

Individuals selected for appointment to the Committee will be invited to serve for up to 3 years. Members are appointed as SGEs and receive a stipend and reimbursement for expenses incurred for attending ACCV meetings and/or conducting other business on behalf of the ACCV, as authorized by 5 U.S.C. 5703 for persons employed intermittently in government service.

The following information must be included in the package of materials submitted for each individual nominated for consideration: (1) a letter of nomination stating the name, affiliation, and contact information for the nominee, the basis for the nomination (i.e., what specific attributes, perspectives, and/or skills does the individual possess that would benefit the workings of the ACCV) and the nominee’s field(s) of expertise; (2) the name, address, daytime telephone number, and email address at which the nominator can be contacted; and (3) a current copy of the nominee’s curriculum vitae. The individual being nominated or the person/organization recommending the candidate may submit nomination packages directly to HRSA, which will collect and retain nomination packages to create a pool of possible future ACCV voting members. When a vacancy occurs, HRSA and HHS will review nomination packages from the appropriate category and nominees may be contacted at that time.

HHS endeavors to ensure that the membership of the ACCV is fairly balanced in terms of points of view represented and that individuals from a broad representation of geographic areas, gender, and ethnic and minority groups, as well as individuals with disabilities, are considered for membership. Appointments shall be made without discrimination on the basis of race, age, ethnicity, national origin, gender, disability, sexual orientation, or cultural, religious, or socioeconomic status.

Individuals who are selected to be considered for appointment will be required to provide detailed information regarding their financial holdings, consultancies, and research grants or contracts. Disclosure of this information is required for HRSA ethics officials to determine whether there is a potential conflict of interest between the SGE’s public duties as a member of the ACCV and their private interests, including an appearance of a loss of impartiality as defined by federal laws and regulations, and to identify any required remedial action needed to address the potential conflict.

**Authority:** Under the authorities that established the ACCV, the Federal Advisory Committee Act of October 6, 1972, (Pub. L. 92–463) and section 2119 of the National Childhood Vaccine Injury Act (Pub. L. 99–660, as amended), HRSA is requesting nominations for voting members of the ACCV.

Maria G. Button, 
Director, Executive Secretariat.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of the Secretary**

**Findings of Research Misconduct**

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Findings of research misconduct have been made against Ritankar Majumdar, Ph.D. (Respondent), who was a postdoctoral fellow in the intramural program of the Laboratory of Cellular and Molecular Biology (CMB), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH).

Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically the NCI Intramural Research Program. The administrative actions, including supervision for a period of three (3) years, were implemented beginning on August 15, 2022, and are detailed below.

**FOR FURTHER INFORMATION CONTACT:** Wanda K. Jones, Dr.P.H., Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852. (240) 453–8200.

**SUPPLEMENTARY INFORMATION:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

**Ritankar Majumdar, Ph.D., National Institutes of Health:** Based on the report of an investigation conducted by NIH and analysis conducted by ORI in its oversight review, ORI found that Dr. Ritankar Majumdar, former postdoctoral fellow in the intramural program of the Laboratory of CMB, CCR, NCI, NIH, engaged in research misconduct in research supported by PHS funds, specifically the NCI Intramural Research Program.

ORI found that Respondent engaged in research misconduct by knowingly or recklessly falsifying and/or fabricating data in the following one (1) published paper, one (1) manuscript, three (3) PHS grant applications, and fifteen (15) presentations:


• Biogenesis of Leukotriene B4-Containing Exosomes at the Nuclear Envelope. Manuscript accepted for publication in *Nature Cell Biology* in 2019 and withdrawn (hereafter referred to as the “NCB manuscript”).
  • R01 AI145072–01, “Signal relay during directed cell migration,” submitted to the National Institute of Allergy and Infectious Diseases (NIAID), NIH, on 06/04/2018.
  • R01 AI145072–01A1, “Signal relay during directed cell migration,” submitted to NIAID, NIH, on 04/16/2019.
  • R01 AI152517–01, “Signal relay during directed cell migration,” submitted to NIAID, NIH, on 08/16/2019, funded from 07/10/2020–6/30/2025.
  • LTB4-synthesizing enzymes aggregate on nuclear lipid rafts that bud exosomes to mediate signal relay during neutrophil chemotaxis. Poster Presentation at the University of Maryland (UMD) in 2016 (hereafter referred to as the “UMD 2016 presentation”).

• Exosome secretion as an effective mechanism of LTB4-mediated signal relay in migrating neutrophils. Oral presentation at the American Society for Exosomes and Microvesicles (ASEM) on 10/17/2015 (hereafter referred to as the “ASEM 2015 presentation”).

• Chemotactic gradient amplification through the release of extracellular vesicles during eukaryotic chemotaxis. Oral presentation at Collective Dynamics in Microorganisms and Cellular Systems (CDMCS) on 05/25/2016 (hereafter referred to as the “CDMCS 2016 presentation”).

• Signal Relay is Mediated by Exosome Release during Dictyostelium and Neutrophil Chemotaxis. Oral presentation at International CIM (Cells in Motion) Symposium 2015 on 09/14/2015 (hereafter referred to as the “CIM in Motion) Symposium 2015 on 09/14/2015). (hereafter referred to as the “CIM 2015 presentation”).


• Nuclear Lipid Microdomains as a Novel Niche for Exosome Biogenesis: Interplay of ESCRT Dependent and Independent Processes During Relay of Chemotactic Signals in Neutrophils OR Do ESCRTs DR(ea)M of nuclear MVBS?

Oral presentation at Directed Cell Migration Gordon Research Seminar (GRS) on 01/21/2017 (GRS2017.pptx) (hereafter referred to as the “GRS 2017 presentation”).

• Lab Meeting on 02/13/15 (hereafter referred to as “Lab Meeting 02/13/15”).
• Lab Meeting in August 2015 (hereafter referred to as “Lab Meeting 08/2015”).
• Lab Meeting on October 7, 2016 (hereafter referred to as “Lab Meeting 10/07/2016”).
• Lab Meeting in July 2016 (hereafter referred to as “Lab Meeting 07/2016”).
• A series of fortunate events. Lab Meeting in December 2016 (hereafter referred to as “Lab Meeting 12/2016”).
• Lab Meeting on November 4, 2015 (hereafter referred to as “Lab Meeting 11/04/2015”).

• Exosome secretion as an effective mechanism of LTB4 mediated signal relay in migrating neutrophils. LCMB Presentation in 2015 (hereafter referred to as “LCMB 2015 presentation V1”).

• Exosome secretion as an effective mechanism of LTB4 mediated signal relay in migrating neutrophils. LCMB Presentation in 2015 (hereafter referred to as “LCMB 2015 presentation V2”).

• Extracellular Vesicles mediate signal relay during Chemotaxis. LCMB Seminar in 2014 (hereafter referred to as “LCMB 2014 seminar”).

• Data compilation for LCMB Seminar in 2016 (hereafter referred to as “LCMB 2016 seminar data 1”).

• A series of fortunate events: Do ESCRTs DR(ea)M of nuclear MVBS? Oral presentation at LCMB in 2016 (hereafter referred to as “LCMB 2016 seminar data 2”).

Specifically, ORI found that:

• Respondent knowingly or recklessly falsified and/or fabricated immunoblot results in:

  ➢ Respondent knowingly or recklessly falsified and/or fabricated electron microscopic (EM) image data for the formation of multivesicular bodies (MVBS) in migrating primary neutrophils following chemoattractant activation by:
    —adding and/or removing 5-lipoxygenase (5–LO) immunogold signal and/or cell organelle membranes and/or subcellular vesicles in:
    ➢ NCB manuscript:
      —Figure 1B, also included in:
        • Figure 4C in R01 AI145072–01
        • Figure 3B in R01 AI145072–01A1
        • Slide 8 in Lab Meeting 10/07/2016
        • Slide 2 in Lab Meeting 12/2016
        • Column 2, Row 1 in GRC 2017 presentation 1
      —Figures 1C and 1D
      —Figure 2D, also included in:
        • Slide 14 in Lab Meeting 10/07/2016
        • Slide 3 in Lab Meeting 12/2016

• Column 2 Row 4 in GRC 2017 presentation 1

  ➢ Plos Biology 2016:
    —Figure 2A, also included in:
      • Figure 11 in UMD 2016 presentation
    —Figure 2B, also included in:
      • Slide 20 in LCMB 2015 presentation V1
      • Slide 20 in LCMB 2015 presentation V2
    —Figure 2C, also included in:
      • Slide 20 in LCMB 2015 presentation V1
      • Slide 22 in LCMB 2015 presentation V2
    —Slide 6 in GRS 2017 presentation 2

  ➢ Figure 2Gi, also included in:
    • Figure 3 in R01 AI145072–01
    • Figure 2 in R01 AI145072–01A1
    • Figure 2 in R01 AI152517–01
    • Slide 20 in Lab Meeting 08/2015
    • Slide 5 in Lab Meeting 07/2016
    • Slide 17 in Lab Meeting 11/04/2015
    • Slide 18 in LCMB 2015 presentation V1
    • Slide 68 in LCMB 2015 presentation V2
    • Slides 7 and 13 in LCMB 2016 seminar data 1
    • Slides 6 and 12 in LCMB 2016 seminar data 2
    • Figure 1b in UMD 2016 presentation
    • Slide 16 in ASEM 2015 presentation
    • Slide 32 in CDMCS 2016 presentation
    • Slide 46 in CIM 2015 presentation
    • Column 1, Row 4 in GRC 2017 presentation 1
    • Slides 10 and 12 in GRS 2017 presentation 2

  ➢ R01 AI145072–01A1:
    —Figure 3D, also included in:
      • Figure 3D in R01 AI152517–01
      • Figure 4Dii in AI145072–01A1
      • Slide 4 in Lab Meeting 12/2016

—presenting EM images from the same source and falsely relabeling them to represent different experimental results in:

  ➢ Figures 1A and 7D in the NCB manuscript
  ➢ Figures 2A and 2D in *PLoS Biology* 2016

• Respondent knowingly or recklessly falsified and/or fabricated immunoblot image data for chemoattractant activation of MVBS in migrating primary neutrophils in:

—Supplemental Figure 2B of the NCB manuscript:
  ➢ by copying the panel representing “5–LO” in Figure 1C in *PLoS Biology* 2016, and flipping, re-sizing, and relabeling it to represent “Flotillins”
  ➢ by copying the panel representing
discuss with Respondent of the primary data represented in those documents and will include a certification to ORI that the data presented in the proposed application, report, manuscript, or abstract are accurately and truthfully represented and that the data, procedures, and methodology are accurately reported and not plagiarized in the application, report, manuscript, or abstract.

(4) If no supervision plan is provided to ORI, Respondent will provide certification to ORI at the conclusion of the Supervision Period that his participation was not proposed on a research project for which an application for PHS support was submitted and that he has not participated in any capacity in PHS-supported research.

(5) During the Supervision Period, Respondent will exclude himself voluntarily from serving in any advisory or consultant capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee.

Dated: September 1, 2022.

Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant Secretary for Health.

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Epidemiology Cohort Studies.

Date: October 13, 2022.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W254, Rockville, Maryland 20850 (Telephone Conference Call).
Contact Person: Susan Lynn Spence, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W254, Rockville, Maryland 20850, 240–620–0819, susan.spence@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; Technologies for Global Health.

Date: October 14, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W608, Rockville, Maryland 20850 (Telephone Conference Call).
Contact Person: Saejeong J. Kim, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W608, Rockville, Maryland 20850, 240–276–5856, nadeem.khan@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–4: NCI Clinical and Translational Cancer Research.

Date: October 18, 2022.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850 (Telephone Conference Call).
Contact Person: Saejeong J. Kim, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850, 240–276–7684, saejeong.kim@nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; Therapeutics for Pediatric and Rare Cancers.

Date: October 14, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850 (Telephone Conference Call).
Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch,